NCT03591731View on ClinicalTrials.gov

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

July 9, 2021

Study Completion Date

December 15, 2024

Conditions
Neuroendocrine Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab 3 mg/kg every 2 weeks

DRUG

Ipilimumab

Ipilimumab 1 mg/kg every 6 weeks

Trial Locations (7)

89011

Auxerre - CH, Auxerre

Unknown

Centre Hospitalier du Pays d'Aix, Aix-en-Provence

CHU d'Amiens-Picardie, Amiens

CHU d'Angers, Angers

Avignon - CH, Avignon

Lyon - Hôpital Edouard Herriot, Lyon

Paris - Curie, Paris

All Listed Sponsors
collaborator

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

collaborator

Federation Francophone de Cancerologie Digestive

OTHER

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT03591731 - Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | Biotech Hunter | Biotech Hunter